Skip to main content
. 2018 Oct 1;2018(10):CD002252. doi: 10.1002/14651858.CD002252.pub4

Comparison 7. Any antihypertensive versus beta blocker (subgrouped by class of drug).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Severe hypertension 10 692 Risk Ratio (M‐H, Fixed, 95% CI) 1.18 [0.95, 1.48]
1.1 Methyldopa versus beta blocker 9 592 Risk Ratio (M‐H, Fixed, 95% CI) 1.36 [1.08, 1.71]
1.2 Calcium channel blocker versus beta blocker 1 100 Risk Ratio (M‐H, Fixed, 95% CI) 0.47 [0.21, 1.05]
2 Proteinuria/pre‐eclampsia 12 1107 Risk Ratio (M‐H, Random, 95% CI) 1.21 [0.88, 1.67]
2.1 Methyldopa versus beta blockers 10 903 Risk Ratio (M‐H, Random, 95% CI) 1.22 [0.86, 1.72]
2.2 Calcium channel blocker versus beta blocker 2 204 Risk Ratio (M‐H, Random, 95% CI) 0.89 [0.19, 4.17]
3 Total reported fetal or neonatal death (including miscarriage) 19 1652 Risk Ratio (M‐H, Random, 95% CI) 1.23 [0.81, 1.88]
3.1 Methyldopa versus beta blockers 16 1280 Risk Ratio (M‐H, Random, 95% CI) 1.25 [0.67, 2.34]
3.2 Calcium channel blokers versus beta blockers 3 372 Risk Ratio (M‐H, Random, 95% CI) 1.21 [0.68, 2.16]
4 Small‐for‐gestational age 7 680 Risk Ratio (M‐H, Random, 95% CI) 1.13 [0.80, 1.60]
4.1 Methyldopa versus beta blockers 6 577 Risk Ratio (M‐H, Random, 95% CI) 1.19 [0.76, 1.84]
4.2 Calcium channel blockers versus beta blockers 1 103 Risk Ratio (M‐H, Random, 95% CI) 1.04 [0.59, 1.83]
5 Preterm birth (< 37 weeks) 9 806 Risk Ratio (M‐H, Random, 95% CI) 1.22 [0.90, 1.67]
5.1 Methyldopa versus beta blockers 8 694 Risk Ratio (M‐H, Random, 95% CI) 1.11 [0.77, 1.60]
5.2 Calcium channel blockers versus beta blockers 1 112 Risk Ratio (M‐H, Random, 95% CI) 1.61 [0.87, 2.97]
6 Maternal death 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
6.1 Calcium channel blockers versus beta blockers 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
7 Severe pre‐eclampsia 1 311 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.43, 1.77]
7.1 Methyldopa versus beta blockers 1 311 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.43, 1.77]
8 Eclampsia 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
8.1 Calcium channel blockers versus beta blockers 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
9 HELLP syndrome 2 212 Risk Ratio (M‐H, Random, 95% CI) 0.56 [0.12, 2.60]
9.1 Calcium channel blockers versus beta blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 0.56 [0.12, 2.60]
10 Pulmonary oedema 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
10.1 Calcium channel blockers versus beta blockers 1 112 Risk Ratio (M‐H, Random, 95% CI) 0.0 [0.0, 0.0]
11 Need for additional antihypertensive drug/s 12 1065 Risk Ratio (M‐H, Random, 95% CI) 1.15 [0.76, 1.75]
11.1 Methyldopa versus beta blockers 10 853 Risk Ratio (M‐H, Random, 95% CI) 1.31 [0.78, 2.20]
11.2 Calcium channel blockers versus beta blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 0.79 [0.31, 1.97]
12 Elective delivery (induction of labour + elective caesarean section) 6 553 Risk Ratio (M‐H, Random, 95% CI) 1.01 [0.91, 1.12]
12.1 Methyldopa versus beta blockers 5 453 Risk Ratio (M‐H, Random, 95% CI) 0.99 [0.89, 1.11]
12.2 Calcium channel blockers versus beta blockers 1 100 Risk Ratio (M‐H, Random, 95% CI) 1.12 [0.87, 1.45]
13 Caesarean section 13 1344 Risk Ratio (M‐H, Random, 95% CI) 1.03 [0.90, 1.17]
13.1 Methyldopa versus beta blockers 10 972 Risk Ratio (M‐H, Random, 95% CI) 1.04 [0.88, 1.23]
13.2 Calcium channel blockers versus beta blockers 3 372 Risk Ratio (M‐H, Random, 95% CI) 0.97 [0.72, 1.29]
14 Induction of labour 2 280 Risk Ratio (M‐H, Random, 95% CI) 0.94 [0.68, 1.31]
14.1 Methyldopa versus beta blockers 1 120 Risk Ratio (M‐H, Random, 95% CI) 1.0 [0.65, 1.53]
14.2 Calcium channel blockers versus beta blockers 1 160 Risk Ratio (M‐H, Random, 95% CI) 0.87 [0.52, 1.45]
15 Antenatal hospital admission 2 275 Risk Ratio (M‐H, Random, 95% CI) 1.78 [0.54, 5.90]
15.1 Methyldopa versus beta blockers 2 275 Risk Ratio (M‐H, Random, 95% CI) 1.78 [0.54, 5.90]
16 Placental abruption 3 385 Risk Ratio (M‐H, Random, 95% CI) 0.93 [0.14, 6.28]
16.1 Methyldopa versus beta blockers 1 173 Risk Ratio (M‐H, Random, 95% CI) 0.49 [0.05, 5.35]
16.2 Calcium channel blockers versus beta blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 2.90 [0.12, 69.62]
17 Maternal side‐effects 7 514 Risk Ratio (M‐H, Random, 95% CI) 1.27 [0.64, 2.53]
17.1 Methyldopa versus beta blockers 5 302 Risk Ratio (M‐H, Random, 95% CI) 4.55 [0.48, 43.24]
17.2 Calcium channel blockers versus beta blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 0.72 [0.44, 1.17]
18 Changed/stopped drugs due to maternal side‐effects 6 484 Risk Ratio (M‐H, Random, 95% CI) 0.64 [0.23, 1.80]
18.1 Methyldopa versus beta blockers 4 272 Risk Ratio (M‐H, Random, 95% CI) 0.36 [0.01, 8.64]
18.2 Calcium channel blockers versus beta blockers 2 212 Risk Ratio (M‐H, Random, 95% CI) 0.69 [0.23, 2.04]
19 Admission to neonatal or intensive care nursery 6 773 Risk Ratio (M‐H, Random, 95% CI) 1.10 [0.84, 1.45]
19.1 Methyldopa versus beta blockers 4 571 Risk Ratio (M‐H, Random, 95% CI) 1.09 [0.80, 1.49]
19.2 Calcium channel blockers versus beta blockers 2 202 Risk Ratio (M‐H, Random, 95% CI) 1.14 [0.63, 2.05]
20 Respiratory distress syndrome 2 221 Risk Ratio (M‐H, Random, 95% CI) 1.37 [0.71, 2.66]
20.1 Methyldopa versus beta blockers 1 118 Risk Ratio (M‐H, Random, 95% CI) 1.17 [0.42, 3.26]
20.2 Calcium channel blockers versus beta blockers 1 103 Risk Ratio (M‐H, Random, 95% CI) 1.54 [0.65, 3.66]
21 Neonatal hypoglycaemia 6 542 Risk Ratio (M‐H, Random, 95% CI) 1.11 [0.62, 2.00]
21.1 Methyldopa versus beta blockers 5 439 Risk Ratio (M‐H, Random, 95% CI) 1.01 [0.49, 2.11]
21.2 Calcium channel blockers versus beta blockers 1 103 Risk Ratio (M‐H, Random, 95% CI) 1.31 [0.49, 3.50]
22 Neonatal bradycardia 2 146 Risk Ratio (M‐H, Random, 95% CI) 0.33 [0.01, 8.02]
22.1 Methyldopa versus beta blockers 2 146 Risk Ratio (M‐H, Random, 95% CI) 0.33 [0.01, 8.02]
23 Neonatal jaundice 2 146 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.44, 2.09]
23.1 Methyldopa versus beta blockers 2 146 Risk Ratio (M‐H, Random, 95% CI) 0.95 [0.44, 2.09]